Patents by Inventor Eloise VAN DER MERWE

Eloise VAN DER MERWE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • A METHOD OF DECREASING CONCENTRATION OF TAU (T) PROTEIN AND/OR PHOSPHORYLATED TAU (T) PROTEIN
    Publication number: 20230212250
    Abstract: This disclosure relates to a method of decreasing concentration of tau (?) protein and/or phosphorylated tau (?) protein in a target cell of a human or animal subject having Alzheimer's Disease (AD). The disclosure extends to use of biopharmaceutical agents including (i). 37 kDa/67 kDa laminin receptor precursor/high affinity laminin receptor (LRP/LR) and/or a fragment thereof, or (ii). a transfecting agent for the expression of LRP/LR, for use in treating Alzheimer's Disease (AD).
    Type: Application
    Filed: May 11, 2020
    Publication date: July 6, 2023
    Applicant: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventors: Stefan Franz Thomas WEISS, Katelyn CUTTLER, Tyrone Chad OTGAAR, Eloise VAN DER MERWE, Monique J. BIGNOUX
  • COMPOUNDS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE
    Publication number: 20220160824
    Abstract: LRP/LR for use in the treatment and/or prevention of Parkinson's disease (PD). Pharmaceutical compositions comprising LRP/LR for use in the treatment of Parkinson's Disease (PD), and a method of maintaining concentration levels of dopamine within a human or animal body.
    Type: Application
    Filed: November 28, 2019
    Publication date: May 26, 2022
    Applicant: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventors: Stefan Franz Thomas WEISS, Eloise VAN DER MERWE, Katelyn CUTTLER, Monique BIGNOUX, Jessica BURNS
  • BIOPHARMACEUTICAL AGENTS FOR USE IN REDUCING LIPID CONTENT IN CELLS
    Publication number: 20210277084
    Abstract: A biopharmaceutical agent including a 37 kDa/67 kDa laminin receptor precursor/high affinity laminin receptor (LRP/LR) and/or a fragment thereof for use in treatment and/or prevention of atherosclerosis and/or obesity and/or insulin resistance and/or diabetes. The biopharmaceutical agent may be encapsulated by functionalized or non-functionalized nanoparticles, and further may be formulated to include a carrier to provide a pharmaceutical composition for parental or non-parental administration. In use, the biopharmaceutical agent reduces lipid content in target cells. Also, a method of decreasing lipid concentration in a target cell of a human or animal subject.
    Type: Application
    Filed: July 8, 2019
    Publication date: September 9, 2021
    Applicant: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventors: Stefan Franz Thomas WEISS, Tyrone Chad OTGAAR, Eloise VAN DER MERWE, Martin BERNERT, Gavin MORRIS